Timber Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Timber Pharmaceuticals, Inc.
Plus deals involving SK Biopharmaceuticals, Hikma and Proteovant, Day One/Sprint, Eyenovia/Formosa, Clinigen/CNX, Ikena/Pionyr and more.
Keeping Track: US FDA Clears New Uses For Incyte’s Pemazyre, AbbVie’s Imbruvica; Minerva Seeks First Negative Symptoms Claim In Schizophrenia
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Reverse merger takes Histogen public as it seeks mid-stage data for male pattern baldness by end of 2020. AstraZeneca continues divestiture spree, sending five mature hypertension drugs to Atnahs.
A topical foam formulation of the antibiotic, minocycline, is expected to be a novel entrant into the US severe acne market. After positive top-line results from a confirmatory Phase III study, Foamix is stepping-up its financing and marketing plans.
- Topical Delivery
- Drug Delivery
- Other Names / Subsidiaries
- BioPharmX Corporation, Inc.
- Timber Pharmaceuticals LLC
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.